Megan M. Davis

8.0k total citations · 1 hit paper
28 papers, 1.1k citations indexed

About

Megan M. Davis is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Megan M. Davis has authored 28 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 13 papers in Molecular Biology and 8 papers in Immunology. Recurrent topics in Megan M. Davis's work include CAR-T cell therapy research (23 papers), Viral Infectious Diseases and Gene Expression in Insects (7 papers) and Virus-based gene therapy research (5 papers). Megan M. Davis is often cited by papers focused on CAR-T cell therapy research (23 papers), Viral Infectious Diseases and Gene Expression in Insects (7 papers) and Virus-based gene therapy research (5 papers). Megan M. Davis collaborates with scholars based in United States, Czechia and United Kingdom. Megan M. Davis's co-authors include Joseph A. Fraietta, Carl H. June, J. Joseph Melenhorst, Bruce L. Levine, Simon F. Lacey, Michael C. Milone, Rathna Nath, Xiaodong Ren, Gerald P. Schielke and Kevin Wang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Megan M. Davis

28 papers receiving 1.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells

2023 104 citations Sangya Agarwal, M. Ángela Aznar et al. Immunity profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Megan M. Davis United States	12	804	493	288	230	218	28	1.1k
Ryan Cross Australia	14	815 1.0×	410 0.8×	436 1.5×	291 1.3×	173 0.8×	31	1.2k
Leah Alabanza United States	10	481 0.6×	244 0.5×	211 0.7×	178 0.8×	109 0.5×	16	730
Martín Bonamino Brazil	20	332 0.4×	669 1.4×	195 0.7×	90 0.4×	209 1.0×	47	1.1k
Lauren Giuffrida Australia	12	893 1.1×	379 0.8×	705 2.4×	213 0.9×	172 0.8×	14	1.3k
Ana Kostić United States	15	484 0.6×	283 0.6×	109 0.4×	184 0.8×	77 0.4×	39	990
Kristina Wikström Sweden	10	403 0.5×	260 0.5×	226 0.8×	76 0.3×	124 0.6×	22	675
Avraham J. Treves Israel	17	1.1k 1.3×	452 0.9×	913 3.2×	88 0.4×	224 1.0×	25	1.5k
Ashley Woods United States	10	210 0.3×	290 0.6×	88 0.3×	97 0.4×	62 0.3×	17	543
Anton G. Henssen Germany	18	294 0.4×	753 1.5×	86 0.3×	66 0.3×	121 0.6×	48	1.2k
Darya Alizadeh United States	13	942 1.2×	417 0.8×	514 1.8×	393 1.7×	220 1.0×	25	1.3k

Countries citing papers authored by Megan M. Davis

Since Specialization

Citations

This map shows the geographic impact of Megan M. Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Megan M. Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Megan M. Davis more than expected).

Fields of papers citing papers by Megan M. Davis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Megan M. Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Megan M. Davis. The network helps show where Megan M. Davis may publish in the future.

Co-authorship network of co-authors of Megan M. Davis

This figure shows the co-authorship network connecting the top 25 collaborators of Megan M. Davis. A scholar is included among the top collaborators of Megan M. Davis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Megan M. Davis. Megan M. Davis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Engel, Nils W., Israel Steinfeld, Daniel Ryan, et al.. (2025). Quadruple adenine base–edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease–engineered T cells. Proceedings of the National Academy of Sciences. 122(20). e2427216122–e2427216122. 5 indexed citations

Svoboda, Jakub, Daniel J. Landsburg, Sunita D. Nasta, et al.. (2024). Safety and efficacy of armored huCART19-IL18 in patients with relapsed/refractory lymphomas that progressed after anti-CD19 CAR T cells.. Journal of Clinical Oncology. 42(16_suppl). 7004–7004. 11 indexed citations

Jain, Achin, Mercy Gohil, Edward Pequignot, et al.. (2024). HARNESSING POTENT NAÏVE LIKE T CELLS FOR PRECISION CAR T MANUFACTURING. Cytotherapy. 26(6). S135–S135. 1 indexed citations

Jung, In-Young, Estela Noguera-Ortega, Erik F. Williams, et al.. (2023). Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors. Cell Reports Medicine. 4(6). 101053–101053. 36 indexed citations

Agarwal, Sangya, M. Ángela Aznar, Andrew J. Rech, et al.. (2023). Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells. Immunity. 56(10). 2388–2407.e9. 104 indexed citations breakdown →

Jung, In-Young, Vivek Narayan, Andrew J. Rech, et al.. (2022). BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion. Science Translational Medicine. 14(670). eabn7336–eabn7336. 82 indexed citations

Agarwal, Sangya, Tong Da, Shunichiro Kuramitsu, et al.. (2022). Abstract 5571: Disruption of cell-intrinsic checkpoint regulator CTLA-4 in CD19 directed CAR T cells provides clinical efficacy in CLL patients. Cancer Research. 82(12_Supplement). 5571–5571. 2 indexed citations

Cohen, Adam D., Simon F. Lacey, Megan M. Davis, et al.. (2021). The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. Clinical Cancer Research. 27(23). 6580–6590. 23 indexed citations

Nobles, Christopher L., Shantan Reddy, January Salas-McKee, et al.. (2019). iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity. Genome biology. 20(1). 66–78. 53 indexed citations

10.

Salas-McKee, January, Weimin Kong, Whitney L. Gladney, et al.. (2019). CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy. Human Vaccines & Immunotherapeutics. 15(5). 1126–1132. 43 indexed citations

11.

Ghassemi, Saba, Selene Nuñez-Cruz, Roddy S. O’Connor, et al.. (2018). Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells. Cancer Immunology Research. 6(9). 1100–1109. 212 indexed citations

12.

Cohen, Adam D., J. Joseph Melenhorst, Alfred L. Garfall, et al.. (2018). Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM). Blood. 132(Supplement 1). 1974–1974. 10 indexed citations

13.

Gill, Saar, Noelle V. Frey, Elizabeth O. Hexner, et al.. (2018). Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate. Blood. 132(Supplement 1). 298–298. 72 indexed citations

14.

Garfall, Alfred L., Adam D. Cohen, Joseph A. Fraietta, et al.. (2018). Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma. Blood. 132(Supplement 1). 1886–1886. 22 indexed citations

15.

Long, Kristen B., Regina M. Young, Alina C. Boesteanu, et al.. (2018). CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success. Frontiers in Immunology. 9. 2740–2740. 62 indexed citations

16.

Davis, Megan M., David H. McKenna, & Philip J. Norris. (2017). How do i participate in T‐cell immunotherapy?. Transfusion. 57(5). 1115–1121. 1 indexed citations

17.

Davis, Megan M., Andrew D. Fesnak, Yaara Ohayon, et al.. (2017). Predictors of manufacturing (MFG) success for chimeric antigen receptor (CAR) T cells in Non-Hodgkin Lymphoma (NHL). Cytotherapy. 19(5). S118–S119. 8 indexed citations

18.

White‐Gilbertson, Shai, Megan M. Davis, Christina Voelkel‐Johnson, & Laura M. Kasman. (2016). Sex differences in the MB49 syngeneic, murine model of bladder cancer. PubMed. 3(1). 1–1. 6 indexed citations

19.

Levine, Bruce L., et al.. (2015). Personalized gene therapy locks out HIV, paving the way to control virus without antiretroviral drugs. Expert Opinion on Biological Therapy. 15(6). 831–843. 4 indexed citations

20.

Nath, Rathna, Megan M. Davis, Albert W. Probert, et al.. (2000). Processing of cdk5 Activator p35 to Its Truncated Form (p25) by Calpain in Acutely Injured Neuronal Cells. Biochemical and Biophysical Research Communications. 274(1). 16–21. 140 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact